Zeo ScientifiX, Inc. (ZEOX) stock
ZEOXOTCBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
$0.91+0.00 (+0.15%)
Close on Oct 19, 2026Market cap $7.08MP/E –Yield –
Zeo ScientifiX profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Zeo ScientifiX's profit margin for the twelve months ending Apr 30, 2026 was -55.6%. For fiscal 2025 it was -106.2%, against -101.8% the year before. The highest annual figure on record is -15.3% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -106.2% | −4.4 |
| FY2024 | Oct 31, 2024 | -101.8% | +51.5 |
| FY2023 | Oct 31, 2023 | -153.3% | −16.2 |
| FY2022 | Oct 31, 2022 | -137.1% | +90.8 |
| FY2021 | Oct 31, 2021 | -227.9% | +183.9 |
| FY2020 | Oct 31, 2020 | -411.8% | −309.7 |
| FY2019 | Oct 31, 2019 | -102.1% | +256.9 |
| FY2018 | Oct 31, 2018 | -358.9% | +1215.5 |
| FY2017 | Oct 31, 2017 | -1574.5% | −896.6 |
| FY2016 | Oct 31, 2016 | -677.8% | −177.7 |
| FY2015 | Oct 31, 2015 | -500.1% | −366.4 |
| FY2014 | Oct 31, 2014 | -133.8% | −95.0 |
| FY2013 | Oct 31, 2013 | -38.8% | −23.5 |
| FY2012 | Oct 31, 2012 | -15.3% | +49.6 |
| FY2011 | Oct 31, 2011 | -64.9% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | -5.6% | +115.4 |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | -58.9% | +55.1 |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -49.3% | +74.4 |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -158.7% | −68.5 |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | -121.1% | −44.3 |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | -114.0% | +18.5 |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -123.7% | +85.5 |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -90.1% | +69.1 |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -76.7% | +7.2 |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | -132.5% | −26.6 |
| Q4 FY2022CQ3 2022 | Oct 31, 2022 | -209.2% | −151.7 |
| Q3 FY2022CQ2 2022 | Jul 31, 2022 | -159.2% | −56.2 |
| Q2 FY2022CQ1 2022 | Apr 30, 2022 | -83.9% | +441.4 |
| Q1 FY2022CQ4 2021 | Jan 31, 2022 | -105.9% | +579.4 |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -57.5% | +183.0 |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | -103.0% | −3.1 |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | -525.3% | −402.0 |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | -685.3% | −624.8 |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | -240.5% | −69.0 |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | -99.9% | +48.9 |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | -123.3% | +2682.9 |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | -60.5% | −28.9 |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | -171.5% | +183.5 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | -148.9% | +381.9 |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -2806.2% | −725.7 |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -31.6% | +725180.8 |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -355.0% | +941.9 |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -530.7% | +381.8 |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -2080.5% | −1637.5 |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -725212.5% | −724694.9 |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -1296.9% | −994.3 |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -912.5% | +221.6 |
| Q2 FY2016CQ1 2016 | Apr 30, 2016 | -443.1% | – |
| Q1 FY2016CQ4 2015 | Jan 31, 2016 | -517.6% | – |
| Q4 FY2015CQ3 2015 | Oct 31, 2015 | -302.6% | – |
| Q3 FY2015CQ2 2015 | Jul 31, 2015 | -1134.1% | – |
See a number that looks wrong?